Stimulators of soluble guanylyl cyclase: future clinical indications

about

Effect of Shenmai injection on preventing the development of nitroglycerin-induced tolerance in rats

P2860

Q33615764-843ABD11-F6AE-47C6-B6B6-98B5AA6B1B5B

P2860

Stimulators of soluble guanylyl cyclase: future clinical indications

Item

http://www.wikidata.org/entity/Q38093420

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Stimulators of soluble guanylyl cyclase: future clinical indications

@en

type

Item

label

Stimulators of soluble guanylyl cyclase: future clinical indications

@en

prefLabel

Stimulators of soluble guanylyl cyclase: future clinical indications

@en

P1476

Stimulators of soluble guanylyl cyclase: future clinical indications

@en

P2093

Bobby D Nossaman

http://www.w3.org/2001/XMLSchema#string

Philip J Kadowitz

http://www.w3.org/2001/XMLSchema#string

P2860

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme

Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade

Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats

Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations.

Resuscitating the microcirculation in sepsis: the central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials

Early increases in microcirculatory perfusion during protocol-directed resuscitation are associated with reduced multi-organ failure at 24 h in patients with sepsis

NO-independent regulatory site on soluble guanylate cyclase.

Pulmonary hypertension: diagnosis and management

Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.

P304

147-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23532174

http://www.w3.org/2001/XMLSchema#string

P932

3603178

http://www.w3.org/2001/XMLSchema#string

Stimulators of soluble guanylyl cyclase: future clinical indications

about

P2860

P2860

Stimulators of soluble guanylyl cyclase: future clinical indications

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932